Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma

被引：0
|
作者：
Anne von Mässenhausen
Mario Deng
Hannah Billig
Angela Queisser
Wenzel Vogel
Glen Kristiansen
Andreas Schröck
Friedrich Bootz
Friederike Göke
Alina Franzen
Lynn Heasley
Jutta Kirfel
Johannes Brägelmann
Sven Perner
机构：
[1] University Hospital of Bonn,Section of Prostate Cancer Research
[2] University Hospital of Bonn,Institute of Pathology
[3] University Hospital of Bonn,Center for Integrated Oncology Cologne/Bonn
[4] Pathology of the University Hospital of Luebeck,Department of Otorhinolaryngology/Head and Neck Surgery
[5] Department of Pathology,Department of Craniofacial Biology
[6] Leibniz Research Center Borstel,Department of Hematology/Oncology
[7] University Hospital of Bonn,undefined
[8] University of Colorado Anschutz Medical Campus,undefined
[9] University Hospital of Bonn,undefined
来源：
Targeted Oncology | 2016年 / 11卷
关键词：
HSC3 Cell; FGFR3 Mutation; FGFR3 Expression; Human Papilloma Virus Status; Thiazolyl Blue Tetrazolium Bromide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：631 / 642
页数：11
相关论文
共 50 条
  • [31] WHSC1L1 as a therapeutic target in squamous cell carcinoma of the head and neck
    Saloura, Vassiliki
    Vougiouklakis, Theodore
    Lingen, Mark
    Seiwert, Tanguy
    Vokes, Everett
    Nakamura, Yusuke
    Hamamoto, Ryuji
    CANCER RESEARCH, 2015, 75
  • [32] Id-1 gene and protein as therapeutic target for head and neck squamous cell carcinoma
    Murase, Ryuichi
    McAllister, Sean
    Fujita, Yohei
    Sumida, Tomoki
    Nakashiro, Koichi
    Desprez, Pierre
    Hamakawa, Hiroyuki
    CANCER RESEARCH, 2014, 74 (19)
  • [33] MicroRNA-138: A potential therapeutic target for head and neck squamous cell carcinoma (HNSCC)
    Xu, Ji-Liang
    Xia, Rong
    ORAL ONCOLOGY, 2014, 50 (07) : E33 - E33
  • [34] Mammalian target of rapamycin and head and neck squamous cell carcinoma
    Liao, Yu-Min
    Kim, Charles
    Yen, Yun
    HEAD & NECK ONCOLOGY, 2011, 3
  • [35] Therapeutic targets in head and neck squamous cell carcinoma: Identification, evaluation, and clinical translation
    Howard, Jason D.
    Lu, Bo
    Chung, Christine H.
    ORAL ONCOLOGY, 2012, 48 (01) : 10 - 17
  • [36] Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma
    Liu, Shuo
    Qin, Zhen
    Mao, Yaqing
    Zhang, Wenbo
    Wang, Yujia
    Jia, Lingfei
    Peng, Xin
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [37] Novel therapeutic targets in squamous cell carcinoma of the head and neck
    Cohen, EEW
    SEMINARS IN ONCOLOGY, 2004, 31 (06) : 755 - 768
  • [38] Head and neck squamous cell carcinoma: optimizing the therapeutic index
    Rosenthal, DI
    Blanco, AI
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (03) : 501 - 514
  • [39] Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
    Liao, Rachel G.
    Jung, Joonil
    Tchaicha, Jeremy
    Wilkerson, Matthew D.
    Sivachenko, Andrey
    Beauchamp, Ellen M.
    Liu, Qingsong
    Pugh, Trevor J.
    Pedamallu, Chandra Sekhar
    Hayes, D. Neil
    Gray, Nathanael S.
    Getz, Gad
    Wong, Kwok-Kin
    Haddad, Robert I.
    Meyerson, Matthew
    Hammerman, Peter S.
    CANCER RESEARCH, 2013, 73 (16) : 5195 - 5205
  • [40] Mutation of FGFR3 in transitional cell carcinoma
    Sibley, K
    Kennedy, W
    Knowles, M
    BRITISH JOURNAL OF CANCER, 2001, 85 : 79 - 79
12345